{"id":"NCT01777139","sponsor":"GlaxoSmithKline","briefTitle":"A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures","officialTitle":"A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-11","primaryCompletion":"2016-12-14","completion":"2017-09-13","firstPosted":"2013-01-28","resultsPosted":"2019-04-22","lastUpdate":"2020-03-11"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Retigabine IR","otherNames":[]}],"arms":[{"label":"Retigabine IR","type":"EXPERIMENTAL"}],"summary":"This is a multicentre, long-term, open-label extension (OLE) study to assess the long-term safety, tolerability and efficacy of retigabine immediate-release (IR) as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures (POS).","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent (TE) Serious Adverse Events (SAEs) and Non-SAEs","timeFrame":"Up to 4 years","effectByArm":[{"arm":"RTG IR","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":12,"countries":["Malaysia","South Korea","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":30},"commonTop":["Dizziness","Somnolence","Headache","Asthenia","Nasopharyngitis"]}}